Spero Therapeutics Inc (SPRO)
1.00
-0.05
(-4.76%)
USD |
NASDAQ |
Jan 08, 16:00
1.01
+0.01
(+1.00%)
After-Hours: 20:00
Spero Therapeutics SG&A Expense (Quarterly): 5.198M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| CytomX Therapeutics Inc | 7.953M |
| Castle Biosciences Inc | 50.50M |
| Arbutus Biopharma Corp | 4.537M |
| PTC Therapeutics Inc | 73.46M |
| Equillium Inc | 3.278M |